Assisted Fluid Management (AFM) System and Postoperative Outcome After High-risk Abdominal Surgery
NCT06011187
Recruiting
Goal directed fluid therapy (GDFT) or "Personalized fluid therapy" may benefit high-risk surgical patients but these strategies are infrequently implemented. It has also been shown that without any goal or protocol for fluid resuscitation, large inter- and intra-provider variability exist that have been correlated with poor patient outcomes. Recently, an "Assisted Fluid Management" (AFM) system has been developed to help ease some of the work associated with GDFT protocol implementation. The AF... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: University of California IRVINE, Irvine, California +16 locations
Conditions: Decision Support System, Outcome
Register for Updates
TmPSMA-02 in mCRPC
NCT06046040
Recruiting
This is a Phase I, open-label dose finding study to assess the safety, tolerability, manufacturing feasibility, and preliminary efficacy of TmPSMA-02 CAR T cells in patients with metastatic castrate-resistant prostate cancer (mCRPC). Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Register for Updates
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
NCT06107413
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given in combination with Fluorouracil, Folinic Acid, and Bevacizumab to adult participants to treat unresctable metastatic colorectal cancer. ABBV-400 is an investigational drug being developed for the treatment of unresectable metastatic colorectal cancer. Fluorouracil, folinic acid, and bevacizuma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Mayo Clinic Arizona /ID# 262610, Phoenix, Arizona +63 locations
Conditions: Unresectable Metastatic Colorectal Cancer
Register for Updates
A Fruit and Vegetable Prescription Program
NCT06107816
Recruiting
Dietary intake of fruits and vegetables (F\&V) is a cornerstone for the treatment of type 2 diabetes, however less than 16% of Hispanic adults consume the recommended number of servings each day. F\&V prescription (F\&V Rx) programs are embedded into clinical settings and provide patients with vouchers to purchase F\&V at local retailers. The proposed study aims to test the effects of a F\&V Rx on diabetes self-management education and support (DSME/S) uptake and retention, dietary intake of F\&... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Penn State Health St. Joseph Downtown Campus, Reading, Pennsylvania
Conditions: Diabetes Mellitus, Diabetes Complications
Register for Updates
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281
Recruiting
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +849 locations
Conditions: Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Register for Updates
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
NCT06132113
Recruiting
This study is open to adults aged 18 and older or above legal age who have a specific type of advanced neuroendocrine cancer (NEC). Their tumours must be positive for a marker called DLL3. The purpose of this study is to test a medicine called BI 764532 in addition to chemotherapy. The study has 2 parts. Part A of this study aims to find out the highest dose of BI 764532 that people can tolerate in addition to chemotherapy. The purpose of Part B is to find out how well people can tolerate BI 76... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: University of Miami, Miami, Florida +20 locations
Conditions: Neuroendocrine Neoplasms
Register for Updates
CD40 Agonist and PD-1 Inhibitor in HNSCC
NCT06159621
Recruiting
Prospective, open-label, phase 1 study of CD40 agonist (LVGN7409) and PD-1 inhibition (LVGN3616) in patients with resectable Human Papillomavirus (HPV)-negative mucosal head/neck squamous cell carcinoma (HNSCC). This protocol proposes to study the safety and immunological effects of LVGN7409, a CD40 agonistic antibody, when administered in combination with PD-1 inhibition prior to surgical resection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Pregnancy and Contraception Education in Chronic Kidney Disease (PACE-CKD)
NCT06189807
Recruiting
This pilot study will assess the efficacy of a pregnancy and contraception education decision aid (DA) for patients with chronic kidney disease to support decisions about reproductive health, and will assess feasibility and acceptability of the intervention to inform future Research Project Grant (R01) level studies.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
06/24/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: CKD, Chronic Kidney Diseases
Register for Updates
Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG)
NCT06214923
Recruiting
This project examines, in chronic pain, the mechanisms of immersive virtual reality compared to the mechanisms of placebo hypoalgesia. The potential of developing new non-pharmacological premises for low-risk interventions for pain management is high.
Gender:
ALL
Ages:
Between 18 years and 88 years
Trial Updated:
06/24/2025
Locations: Luana Colloca, Baltimore, Maryland +1 locations
Conditions: Pain, Virtual Reality, Placebo, Temporomandibular Disorder
Register for Updates
Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
NCT06225193
Recruiting
In this initial investigator-initiated retrospective study, aim to analyze the enhanced liver fibrosis (ELF) scores in this high-risk population for NAFLD/nonalcoholic steatohepatitis(NASH)-related fibrosis. Study define 'high-risk' to include metabolic syndrome, which can be further defined by an atherosclerotic cardiovascular disease (ASCVD) score \>7.5, any diagnosis of hyperlipidemia, history of coronary artery disease, history of heart failure, hypertension and/or type 2 diabetes. Study wou... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Fatty Liver
Register for Updates
Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)
NCT06234384
Recruiting
The goal of the study is to create a longitudinal study of patient reported outcomes for people living with sarcoidosis that maintains privacy. Patients report on the following: demographics, disease symptoms, diagnostic journey, provider experience, disease treatment, and burden of disease. The goal is to create a natural history of sarcoidosis, support research, and better understand the needs of the sarcoidosis community.
Gender:
ALL
Ages:
7 years and above
Trial Updated:
06/24/2025
Locations: Foundation For Sarcoidosis Research, Chicago, Illinois
Conditions: Sarcoidosis
Register for Updates
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
NCT06240728
Recruiting
NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable and shows a preliminary efficacy in participants with B7-H7 (HHLA2) expressing tumors at selected dose(s). The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? * wh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland +7 locations
Conditions: Metastatic Malignant Neoplasm
Register for Updates